Were you exposed? Infant with measles traveled through these Snohomish and King County locations
An infant in Snohomish County was identified as the latest positive case of measles in the area.
According to the Snohomish County Health Department, the infant was likely exposed to measles during a recent trip abroad.
This is the second case of measles in an infant, and third case overall, in Washington state since Jan 1 of this year.
People in certain King and Snohomish County locations where the infant travelled may have been exposed.
The measles virus can remain in the air for up to two hours after someone contagious with measles leaves the area.
Anyone who was at the following locations during the times listed could have been exposed to measles:
March 27 | 10:45 a.m. to 2 p.m.
Seattle-Tacoma International Airport
S Concourse (Gate S12)
Customs to International Arrivals Facility BaggageClaim (Carousel 20)
Exited the airport out of Gina Marie Arrivals Hall [south end of the main terminal on the lower level]
March 29 | 6:25 p.m. – 10 p.m.
Providence Monroe Clinic 19200 N Kelsey St, Monroe, WA 98272
March 31 | 8:55 a.m. to 12:30 p.m.
Providence Mill Creek Walk-In Care/Western Washington Medical Group Endoscopy clinic/Lobby Cafe (12800 Bothell Everett Hwy #110, Everett, WA 98208)
March 31 | 11 a.m.-1:15 p.m.
Seattle Children's Hospital Forest garage, Forest elevators, Forest pharmacy, and Forest B lobby (4800 Sand Point Way NE, Seattle, WA 98105)
What to do if you were in a location of potential measles exposure, according to the Snohomish County Department of Health:
Most people in our area have immunity to measles through vaccination, so the risk to the general public is low. However, anyone who was in the locations of potential exposure to measles around the times listed should:
Find out if you have been vaccinated for measles or have had measles previously. Make sure you are up to date with the recommended number of measles (MMR) vaccinations.
Call a healthcare provider promptly if you develop an illness with fever or with an unexplained rash. To avoid possibly spreading measles to others, do not go to a clinic or hospital without calling first to tell them you want to be checked for measles after an exposure. It is also important to limit contact with others, especially those without known immunity, and to wear a well-fitting mask if you do need to go to a healthcare facility.
If you were at the locations at the times listed above and are not immune to measles, the most likely time you would become sick would be between April 3 and April 21, 2025. People with weakened immune systems may take longer to experience symptoms.
Measles is a highly contagious and potentially severe disease that causes fever, rash, cough, runny nose, and red, watery eyes. If one person has it, up to 9 out of 10 people nearby will become infected if they are not protected. It mainly spreads through the air after a person with measles coughs or sneezes.
Health officials say the measles vaccine is a highly effective form of defense. Two doses of the measles, mumps and rubella (MMR) vaccine provides about 97% protection against getting infected by measles. That protection lasts a lifetime.
Children need two doses of MMR vaccine: the first dose at age 12-15 months, and the second dose at age 4-6 years. Babies ages 6-11 months should get an early dose if traveling internationally. They will still need two additional doses later.
Measles symptoms begin 7 to 21 days after exposure. Measles is contagious from about 4 days before the rash appears through 4 days after the rash appears. People can spread measles before they have the characteristic measles rash.
Measles can lead to ear infections, diarrhea, pneumonia, and rarely, encephalitis (brain inflammation) or death.
Complications from measles can happen even in healthy people, but those at highest risk include infants and children under 5 years, adults over 20 years, pregnant people, and people with weakened immune systems from medications or underlying disease.
If you are in one of these high-risk groups and were exposed to measles at one of these locations, be sure to contact your health care provider to discuss any steps you need to take to protect yourself or loved ones against complications from measles.
Measles is preventable with the safe and highly effective measles, mumps and rubella (MMR) vaccine. According to the Centers for Disease Control and Prevention (CDC), two doses of the MMR vaccine are about 97% effective at preventing measles and that protection is long lasting.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
3 hours ago
- Miami Herald
Do you need tattoo anesthesia or a measles vaccine? What to know
Health Care Do you need tattoo anesthesia or a measles vaccine? What to know This collection of stories explores health-related decisions, including vaccination and and anesthesia. Measles cases rise across the U.S., prompting questions about the need for additional MMR vaccinations. Vaccinated individuals usually have lifelong immunity, but checking immunization records proves essential. In Miami, some opt for sedation tattooing to alleviate pain and hasten completion. Sedation Ink combines tattoo artistry and medical oversight to ensure client safety and efficiency. Read the stories below. Sedation Ink artists work on a back tattoo for client Dom Groenveld as he is anesthetized at a surgical office on Monday, Jan. 20, 2025, in Miami, Fla. Sedation Ink offers tattooing under anesthesia, allowing clients to complete extensive body art in a single session. By Photo by Matias J. Ocner NO. 1: DO YOU NEED ANESTHESIA TO GET A TATTOO? SEE HOW A MIAMI STUDIO MIXES MEDICINE AND INK What to know about the studio sedation. | Published February 26, 2025 | Read Full Story by Michelle Marchante A 3D graphical representation of a measles virus particle. NO. 2: DID YOU GET THE MEASLES VACCINE IN THE PAST? DO YOU NEED ANOTHER SHOT? HOW TO CHECK What to know about how long it lasts. | Published March 15, 2025 | Read Full Story by Michelle Marchante The summary above was drafted with the help of AI tools and edited by journalists in our News division. All stories listed were reported, written and edited by McClatchy journalists.
Yahoo
3 hours ago
- Yahoo
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 90 patients enrolled and a median treatment duration of ~29 weeks at cutoff Enliven will host a webcast and conference call today, June 13, at 1:30 p.m. ET BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) in an oral presentation at the European Hematology Association (EHA) 2025 Congress taking place June 12-15 in Milan, Italy, and virtually. "Thanks to the success of tyrosine kinase inhibitors (TKIs), patients with CML now have a near-normal life expectancy. As a result, treatment goals have evolved beyond response and survival to also prioritize quality of life and tolerability," said Andreas Hochhaus, Professor of Internal Medicine, Hematology and Oncology and Head of the Department of Hematology and Medical Oncology at the Jena University Hospital, Germany. "However, significant unmet needs remain, particularly related to treatment resistance and intolerance, across all lines of therapy. The data from ELVN-001 are encouraging, showing an efficacy, safety and tolerability profile that compare favorably to approved BCR::ABL1 inhibitors, despite being studied in a more heavily pretreated population. I look forward to future data, which could support ELVN-001 as a promising new option for patients who need better long-term disease management." "We are highly encouraged by the ELVN-001 data, specifically as it relates to the consistency of the cumulative and achieved MMR rates as the Phase 1 trial progresses, with more evaluable patients and longer duration of treatment," said Helen Collins, M.D., Chief Medical Officer of Enliven. "While MMR is the efficacy endpoint in CML, safety and tolerability are equally critical given the chronic nature of the disease. ELVN-001 was reported to be well tolerated across all evaluated doses and had low levels of dose reductions and discontinuations, which we believe is the key sign of a favorable safety and tolerability profile. We believe ELVN-001 has the potential to offer best-in-class efficacy and tolerability, which are key attributes for people living with CML. We look forward to sharing additional data in the future." ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with CML. ELVN-001 Data Highlights Patient Demographics As of the cutoff date of April 28, 2025, 90 patients have been enrolled in the ongoing Phase 1 trial across dose levels ranging from 10 mg once a day (QD) to 80 mg twice a day (BID). The vast majority of patients (80%) remain on study with a median treatment duration of ~29 weeks. Patients enrolled were heavily pretreated: 67% of patients received three or more unique prior TKIs, including 58% of patients who received prior asciminib and 43% of patients who received prior ponatinib. 72% of patients had discontinued their prior TKI due to lack of efficacy. Encouraging ELVN-001 Efficacy Data by 24 Weeks Of the enrolled patients, 53 with typical BCR::ABL1 transcripts and without T315I mutations were evaluable for major molecular response (MMR) by 24 weeks. 25 of 53 (47%) evaluable patients were in MMR by 24 weeks, with 13 of 41 (32%) achieving and 12 of 12 (100%) maintaining MMR. Of those resistant to their last TKI, 14 of 34 (41%) were in MMR by 24 weeks. Of those previously treated with asciminib or ponatinib, 12 of 34 (35%) were in MMR by 24 weeks. All patients who achieved or maintained MMR were still in MMR at the time of data cutoff. These data continued to compare favorably to precedent Phase 1 MMRs for approved BCR::ABL1 TKIs, particularly given the more heavily pretreated patient population in the ELVN-001 clinical trial. Specifically, the achieved MMR rate by 24 weeks of 32% compares favorably with historical data from less heavily pretreated patients receiving asciminib, which showed achieved MMR rates of 24% in the Phase 1 trial and 25% in the ASCEMBL Phase 3 trial. ELVN-001's Safety Profile Consistent with High Selectivity for ABL1 ELVN-001 remains well-tolerated across all evaluated doses. Only 3.4% (3 of 87) of patients had dose reductions due to treatment-emergent adverse events (TEAEs) and 4.6% (4 of 87) of patients discontinued due to TEAEs. The majority of TEAEs were low frequency and low grade, and the hematologic TEAE profile was similar to or better than the approved TKIs. Only 2.3% (2 of 87) of patients experienced ≥ Grade 3 non-hematologic treatment-related AEs. No evidence to date of enhanced cardiovascular toxicity and no treatment-related arterial occlusive events (AOEs). The maximum tolerated dose was not reached, and no exposure-toxicity relationship was observed. ELVN-001 Pharmacokinetic (PK) Profile The PK profile supports once-daily dosing with flexible administration requirements, including the ability to take with or without food. There is low potential for drug-drug interactions, an important advantage given that the average CML patient takes approximately five concurrent medications. "We believe there remains significant opportunity to improve upon existing therapies," said Sam Kintz, Co-founder and Chief Executive Officer of Enliven. "Based on today's encouraging Phase 1 update, we believe ELVN-001 has the potential to compete across all lines of therapy. We believe that precedent registrational trials in CML provide a roadmap for the regulatory pathway for ELVN-001, and the use of biomarker-based endpoints, like MMR, enables smaller, faster studies. Importantly, historical Phase 1 data in late-line CML trials have predicted success in subsequent pivotal trials. Building off this exciting update, we expect to initiate our first head-to-head Phase 3 pivotal trial in 2026 and remain confident in ELVN-001 and its potential positioning in the future in the CML treatment paradigm." The oral presentation titled: "ENABLE: A Phase 1a/1b Study of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated CML" will be presented by Andreas Hochhaus, Professor of Internal Medicine, Hematology and Oncology and Head of the Department of Hematology and Medical Oncology at the Jena University Hospital, Germany later today. A copy of the presentation will be available on the "Program Presentations & Publications" section of the Company's website at Webcast and Conference Call InformationEnliven will host a live webcast and conference call today at 1:30 p.m. ET / 7:30 p.m. CEST. To participate in the live event, please register using this link. Following registration, participants will have access to dial in numbers and a unique passcode should they prefer to participate by phone. The event and accompanying slides can also be accessed by visiting the investor relations section of the Company's website at An archived webcast will be available on the Company's website following the event. About the ENABLE TrialThe ENABLE study (NCT05304377) is a Phase 1 study of ELVN-001 in patients with previously treated CML. The trial is currently in Phase 1a/1b development and is a dose escalation and expansion trial designed to evaluate safety and tolerability and to determine the recommended dose for further clinical evaluation of ELVN-001 in patients with CML with and without T315I mutations that is relapsed, refractory or intolerant to TKIs. Secondary endpoints include pharmacokinetics, MMR by central quantitative reverse transcriptase polymerase chain reaction, duration of MMR, BCR::ABL1 transcript levels and complete hematologic response. Enliven is preparing for the potential start of a pivotal trial for ELVN-001 in 2026. About ELVN-001ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. As a highly selective active site inhibitor, ELVN-001 has a mechanism of action that is complementary to allosteric BCR::ABL1 inhibitors, which may play an increasingly important role in the standard of care. ELVN-001 was also designed to have activity against the T315I mutation, the most common BCR::ABL1 mutation, which confers resistance to nearly all approved TKIs, as well as activity against mutations known to confer resistance to allosteric BCR::ABL1 inhibitors. About Enliven Therapeutics Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado. Forward-Looking StatementsThis press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations and financial condition, or otherwise, based on current beliefs of the management of Enliven, as well as assumptions made by, and information currently available to, management of Enliven. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of, and plans regarding, market opportunities, and expectations regarding Enliven's programs, including ELVN-001; expected milestones for ELVN-001, including the potential timing for a start of a pivotal trial for ELVN-001; and statements by Enliven's Chief Executive Officer, Chief Medical Officer and the Professor of Internal Medicine, Hematology and Oncology and Head of the Department of Hematology and Medical Oncology at the Jena University Hospital, Germany. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation: the limited operating history of Enliven; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize or license, or identify and complete strategic alternatives for, product candidates; the outcome of preclinical testing and early clinical trials for product candidates and the potential that the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, including extrapolations or predictions regarding the safety and efficacy of ELVN-001 based on comparisons to published results of trials of other products, which may be different when evaluated in head-to-head studies; Enliven's limited resources; the risk of failing to demonstrate safety and efficacy of product candidates; Enliven's limited experience as a company in designing and conducting clinical trials; the potential for interim, topline, and preliminary data from Enliven's preclinical studies and clinical trials to materially change from the final data; potential delays or difficulties in the enrollment or maintenance of patients in clinical trials; developments relating to Enliven's competitors and its industry, including competing product candidates and therapies; the potential market opportunity for any of Enliven's programs; the decision to develop or seek strategic collaborations to develop Enliven's current or future product candidates in combination with other therapies and the cost of combination therapies; the ability to attract, hire, and retain highly skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any patent protection Enliven obtains or the loss of any of Enliven's patent protection; reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations and strategic partners; geo-political developments, general market or macroeconomic conditions; Enliven's ability to obtain additional capital to fund Enliven's general corporate activities and to fund Enliven's research and development; and other risks and uncertainties, including those more fully described in Enliven's filings with the Securities and Exchange Commission (SEC), which may be found in the section titled "Risk Factors" in Enliven's Annual and Quarterly Reports on Form 10-K and 10-Q filed with the SEC and in Enliven's future reports to be filed with the SEC. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Head-to-Head Comparisons The Company has not performed any head-to-head trials for ELVN-001. As a result, the data referenced in this press release is derived from different clinical trials at different points in time, with differences in trial design and patient populations. As a result, conclusions from cross-trial comparisons cannot be made. View original content to download multimedia: SOURCE Enliven Therapeutics, Inc. Sign in to access your portfolio
Yahoo
10 hours ago
- Yahoo
Alberta's measles outbreaks are now the worst in nearly half a century
Alberta's measles surge is so dramatic, the last time case counts were higher Calgary did not have an NHL team, O Canada was not yet the official national anthem and gasoline would set you back 24 cents a litre. The province reported 29 more cases on Thursday, bringing the total since the outbreaks began in March to 868. That pushes the province past the levels seen during a surge in 1986, when 854 cases were reported. A higher case count hasn't been recorded since 1979. "It's a little shocking. The numbers we're looking at now today really haven't been seen in Alberta since the 1970s," said Craig Jenne, a professor in the department of microbiology, immunology and infectious diseases at the University of Calgary. "[We're] really going back to an era where the vaccine program really was just getting started. We're going back to, really, pre-vaccination times here in Alberta," he said. While there had been earlier versions of a measles vaccine, Alberta launched its routine immunization program for a single dose of the MMR (measles, mumps and rubella) vaccine in 1982. According to the Public Agency of Canada, the rollout of the single MMR dose took place across the country between 1974 and 1983. Two doses of the vaccine became routine between 1996 and 1997. "By the time we got into the early 1980s, for the most part most children in Canada were vaccinated and measles became a thing largely of the past," said Jenne, who's also the deputy director of the Snyder Institute for Chronic Diseases. "There were years with significant outbreaks, including 1986, but as the numbers reveal today we've eclipsed even those outbreaks. So we really have thrown the province back into a situation where we're looking much like Canada did before we had open access to measles vaccines." According to the Alberta government, the highest recorded measles case count was in 1957, when 12,337 cases were reported. Health officials are cautioning that this year's official case count is just the "tip of the iceberg" and that there are cases in the province going unreported and undetected. The south, central and north zones continue to be the hardest hit. A standing measles exposure advisory remains in effect for southern Alberta due to widespread transmission. On Thursday, Alberta Health Services also issued a standing advisory for the following locations within the north zone, due to high case numbers and concern about broader transmission: The Hamlet of La Crete St. Theresa General Hospital in Fort Vermilion Northwest Health Centre in High Level "Unfortunately we've seen this threshold coming now for several weeks when we had seen the establishment of community level transmission, where vaccine rates simply aren't high enough to stop community spread," said Jenne. As of June 7, a total of 75 Albertans had been hospitalized due to measles since the outbreaks began, including 12 people who ended up in intensive care. The vast majority of cases have been among the unimmunized, according to provincial data. Alberta is offering an early and extra measles vaccine dose to babies as young as six months old who are living in the south, central and north zones. Measles can lead to serious complications including pneumonia, brain inflammation, premature delivery and death. Children under the age of five, pregnant Albertans and those with weakened immune systems are the most vulnerable. Measles symptoms include: High fever. Cough. Runny nose. Red eyes. A blotchy, red rash that appears three to seven days after the fever starts. In darker skin colours, it may appear purple or darker than surrounding skin. Alberta Health provides detailed information on measles case counts, symptoms and free immunizations here. A measles hotline is available for people with questions about symptoms, immunization records or to book an appointment: 1-844-944-3434. AHS is advising anyone with measles symptoms to stay home and call the hotline before visiting any hospital, medical clinic or pharmacy.
